Inspiring Confidence in Every Dose

Accessible, high-quality medicine you can trust—delivered with excellence and care since 1966.

OUR VISION

We believe access to medicine is a fundamental right, not a privilege. We aspire to deliver the right pharmaceutical products to patients across the globe.

OUR MISSION

We strive to enhance global access to medicine through a diverse portfolio of products. Our goal is to be a trusted employer, partner, supplier, and sound investment—earning and inspiring confidence at every step.

Our Milestones

1966

2014

2019

2020

2021

2022

2024

2025

Founded in Taiwan

Lotus and Alvogen merge Asian operations

Lotus launched its first P4 product Buprenorphine/naloxone in the US.

Qsymia® launch in Korea

Petroleum Authority of Thailand (PTT) invested in Lotus, strategic partnership in southeast Asia

Lotus launched Lenalidomide in the US; Acquisition of Alimta® and Cialis® from Eli Lilly for Taiwan

Acquisition of Teva pharma Thailand; Acquisition of Alpha Choay ® from Sanofi for Vietnam

Acquisition of Alvogen US, creating a top 20 global specialty pharma powerhouse

Commitment to Quality

Certified by leading global regulatory authorities—including the U.S. FDA, EU EMA, Japan PMDA, Taiwan TFDA, China NMPA, and Brazil ANVISA—our manufacturing sites meet the highest global standards for safety, efficacy, and quality of our products.

We uphold rigorous quality management across every stage of production and cultivate a company‑wide culture where quality is foundational. This commitment ensures our products consistently earn the trust of patients, healthcare providers, and global partners.

Here are a few articles that you might find interesting

Lotus Pharmaceutical Announces Favorable U.S. Appeals Court Ruling on Norwich’s Application for Generic Rifaximin

Business

Aug 26, 2026

Lotus Pharmaceutical Announces Favorable U.S. Appeals Court Ruling on Norwich’s Application for Generic Rifaximin

Taipei, Taiwan and Morristown, N.J., 26 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that Norwich Pharmaceuticals, Inc. (“Norwich”), a wholly ow...

Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets

Business

Aug 21, 2026

Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets

Taipei, Taiwan, 21 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, today announced a strategic licensing and commercialization agreement with Alvotech (N...

Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan

Business

Aug 19, 2026

Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan

Taipei, Taiwan, 19 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that its generic version of POMALYST® (pomalidomide) capsules, in 1 mg, 2 mg, 3 mg and 4...

Inspiring Confidence in Every Dose

OUR VISION

OUR MISSION

Our Milestones

Commitment to Quality

Here are a few articles that you might find interesting

Contact Us